HLHIX Mutual Fund

NAV$28.27

Fund Essentials - as of Mar 31, 2026

Net Assets
$5M
Expense Ratio
1.05%
Dividend Yield (Current)
-
Holdings
24
Inception Date
Dec 22, 2014
Fund Family
Virtus Investment Partners
Investment Style
••••••••••
Asset Class
••••••••••
Legal Structure
••••••••••
Dividend Frequency
Annually

Performance

YTD-8.51%
1 Year+4.98%
3 Year+1.01%
5 Year+5.23%
10 Year+8.64%

Asset Allocation

Stocks: 100.00%

Top Holdings

View All →
TickerNameWeight
LLYEli Lilly & Co13.30%
MCKMckesson Corp5.57%
ABBVAbbvie Inc5.09%
VRTXNvaesrtex Pharmaceuticals Inc5.09%
MRKMerck & Company Inc5.05%
Top 10 Concentration: 55.84%Report Date: Mar 31, 2026
Download all 24 holdings for HLHIX
CSV export with sector, industry & share changes
Get CSV

Dividend Summary

View Details →
Frequency
Annually
Latest Distribution
$7.49
-

Peer Comparison

Benchmark
••••••••••
Outperforming by ••••%
Ranked #••• of •,••• funds
This Mutual Fund
+••.••%
Peer Avg
+••.••%
Premium Feature
Sign in to unlock peer comparison, category rankings and more

HLHIX Mutual Fund Overview

HLHIX Mutual Fund (Virtus KAR Health Sciences Fund Institutional Class) is managed by Virtus Investment Partners with $4.7M in net assets. HLHIX expense ratio is 1.05%, holding 24 positions across sectors including Health Care, Unknown, Consumer Staples. Inception date: 2014-12-22.

HLHIX performance shows a YTD return of -8.51%. The 1-year return is 4.98% and the 5-year return is 5.23%.

HLHIX top holdings include Eli Lilly & Co (13.3%), Mckesson Corp (5.6%), Abbvie Inc (5.1%), Nvaesrtex Pharmaceuticals Inc (5.1%), Merck & Company Inc (5.0%). View all HLHIX holdings, sector breakdown, or dividend history.

HLHIX can be compared against other funds using the overlap calculator or side-by-side comparison tool. HLHIX alternatives are available via the screener, along with tax-loss harvesting opportunities.